
Relx PLC ADR
Industrials · USD
Price
$33.59
Cap
$60.2B
Earnings
0/2 beat
30d Trend
+1%
Lower half of range — may offer entry value
Target range: $47.2 – $57 (consensus: $52.1)
Consensus: Strong Buy
Earnings history
FY 2025
MET
vs
H1 2025
MET
vs
Key macro factors
Economic Growth and Inflation: As an information and analytics provider, RELX's revenue streams from its diverse client base in scientific, medical, legal, and risk management sectors are sensitive to overall economic health. Strong GDP growth and stable inflation typically lead to healthier client budgets for RELX's subscription services and events, whereas rising inflation (like current US CPI and PCE data suggest) or economic slowdowns could prompt budget tightening and impact demand.
Interest Rates and Monetary Policy: The current global market conditions, with anticipated US Q4 GDP and February PCE/CPI data, heavily influence central bank decisions on interest rates. Higher interest rates can increase borrowing costs for RELX and its clients, potentially slowing investment and expansion across industries, which could in turn reduce demand for RELX's information and decision tools.
Geopolitical Stability and Global Economic Uncertainty: Escalating conflicts, such as in the Middle East, and their impact on global commodity prices like oil, can create widespread economic uncertainty. While RELX's core business is not directly tied to these events, significant geopolitical instability can lead to a general reduction in corporate spending and investor confidence across all sectors, indirectly affecting RELX's operational environment and client investment decisions.
RELX is a global provider of information-based analytics and decision tools for professional and business customers in various industries, serving sectors such as science and medical research, risk management, legal, and organizing large-scale digital and face-to-face events like industry trade shows.
QUANT SCORE
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.
